Dan Fan1,2, Jennifer Ma2, Andrew C Bell2, Andries H Groen3, Kyrie S Olsen2, Benjamin H Lok2,4, Jonathan E Leeman2,5, Erik Anderson2, Nadeem Riaz2, Sean McBride2, Ian Ganly6, Ashok R Shaha6, Eric J Sherman7, C Jillian Tsai2, Jung J Kang2, Nancy Y Lee2. 1. Department of Radiation Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China. 2. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. 3. Department of Surgical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 4. Department of Radiation Oncology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada. 5. Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts. 6. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. 7. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Abstract
BACKGROUND: The role of radiotherapy (RT) in the treatment of patients with anaplastic thyroid cancer (ATC) for local tumor control is critical because mortality often is secondary to complications of tumor volume rather than metastatic disease. Herein, the authors report the long-term outcomes of RT for patients with ATC. METHODS: A total of 104 patients with histologically confirmed ATC were identified who presented to the study institution between 1984 and 2017 and who received curative-intent or postoperative RT. Locoregional progression-free survival (LPFS), overall survival (OS), and distant metastasis-free survival were assessed. RESULTS: The median age of the patients was 63.5 years. The median follow-up was 5.9 months (interquartile range, 2.7-17.0 months) for the entire cohort and 10.6 months (interquartile range, 5.3-40.0 months) for surviving patients. Thirty-one patients (29.8%) had metastatic disease prior to the initiation of RT. Concurrent chemoradiation was administered in 99 patients (95.2%) and 53 patients (51.0%) received trimodal therapy. Systemic therapy included doxorubicin (73.7%), paclitaxel with or without pazopanib (24.3%), and other systemic agents (2.0%). The 1-year OS and LPFS rates were 34.4% and 74.4%, respectively. On multivariate analysis, RT ≥60 Gy was associated with improved LPFS (hazard ratio [HR], 0.135; P = .001) and improved OS (HR, 0.487; P = .004), and trimodal therapy was associated with improved LPFS (HR, 0.060; P = .017). The most commonly observed acute grade 3 adverse events included dermatitis (20%) and mucositis (13%), with no grade 4 subacute or late adverse events noted (adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events [version 4.0]). CONCLUSIONS: RT appears to demonstrate a dose-dependent, persistent LPFS and OS benefit in patients with locally advanced ATC with an acceptable toxicity profile. Aggressive RT should be strongly considered for the treatment of patients with ATC as part of a trimodal treatment approach.
BACKGROUND: The role of radiotherapy (RT) in the treatment of patients with anaplastic thyroid cancer (ATC) for local tumor control is critical because mortality often is secondary to complications of tumor volume rather than metastatic disease. Herein, the authors report the long-term outcomes of RT for patients with ATC. METHODS: A total of 104 patients with histologically confirmed ATC were identified who presented to the study institution between 1984 and 2017 and who received curative-intent or postoperative RT. Locoregional progression-free survival (LPFS), overall survival (OS), and distant metastasis-free survival were assessed. RESULTS: The median age of the patients was 63.5 years. The median follow-up was 5.9 months (interquartile range, 2.7-17.0 months) for the entire cohort and 10.6 months (interquartile range, 5.3-40.0 months) for surviving patients. Thirty-one patients (29.8%) had metastatic disease prior to the initiation of RT. Concurrent chemoradiation was administered in 99 patients (95.2%) and 53 patients (51.0%) received trimodal therapy. Systemic therapy included doxorubicin (73.7%), paclitaxel with or without pazopanib (24.3%), and other systemic agents (2.0%). The 1-year OS and LPFS rates were 34.4% and 74.4%, respectively. On multivariate analysis, RT ≥60 Gy was associated with improved LPFS (hazard ratio [HR], 0.135; P = .001) and improved OS (HR, 0.487; P = .004), and trimodal therapy was associated with improved LPFS (HR, 0.060; P = .017). The most commonly observed acute grade 3 adverse events included dermatitis (20%) and mucositis (13%), with no grade 4 subacute or late adverse events noted (adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events [version 4.0]). CONCLUSIONS: RT appears to demonstrate a dose-dependent, persistent LPFS and OS benefit in patients with locally advanced ATC with an acceptable toxicity profile. Aggressive RT should be strongly considered for the treatment of patients with ATC as part of a trimodal treatment approach.
Authors: Robert L Foote; Julian R Molina; Jan L Kasperbauer; Ricardo V Lloyd; Bryan McIver; John C Morris; Clive S Grant; Geoffrey B Thompson; Melanie L Richards; Ian D Hay; Robert C Smallridge; Keith C Bible Journal: Thyroid Date: 2010-12-16 Impact factor: 6.568
Authors: Todd A Pezzi; Abdallah S R Mohamed; Tommy Sheu; Pierre Blanchard; Vlad C Sandulache; Stephen Y Lai; Maria E Cabanillas; Michelle D Williams; Christopher M Pezzi; Charles Lu; Adam S Garden; William H Morrison; David I Rosenthal; Clifton D Fuller; G Brandon Gunn Journal: Cancer Date: 2016-12-27 Impact factor: 6.860
Authors: Eric J Sherman; Su Hsien Lim; Alan L Ho; Ronald A Ghossein; Matthew G Fury; Ashok R Shaha; Michael Rivera; Oscar Lin; Suzanne Wolden; Nancy Y Lee; David G Pfister Journal: Radiother Oncol Date: 2011-10-06 Impact factor: 6.280
Authors: Iñigo Landa; Tihana Ibrahimpasic; Laura Boucai; Rileen Sinha; Jeffrey A Knauf; Ronak H Shah; Snjezana Dogan; Julio C Ricarte-Filho; Gnana P Krishnamoorthy; Bin Xu; Nikolaus Schultz; Michael F Berger; Chris Sander; Barry S Taylor; Ronald Ghossein; Ian Ganly; James A Fagin Journal: J Clin Invest Date: 2016-02-15 Impact factor: 14.808
Authors: Renaud De Crevoisier; Eric Baudin; Anne Bachelot; Sophie Leboulleux; Jean-Paul Travagli; Bernard Caillou; Martin Schlumberger Journal: Int J Radiat Oncol Biol Phys Date: 2004-11-15 Impact factor: 7.038
Authors: Pascal K C Jonker; John Turchini; Schelto Kruijff; Jia Feng Lin; Anthony J Gill; Thomas Eade; Ahmad Ahniss; Roderick Clifton-Bligh; Diana Learoyd; Bruce Robinson; Venessa Tsang; Anthony Glover; Stanley Sidhu; Mark Sywak Journal: Ann Surg Oncol Date: 2021-05-25 Impact factor: 5.344
Authors: Mark Lee; Brian R Untch; Bin Xu; Ronald Ghossein; Catherine Han; Fengshen Kuo; Cristina Valero; Zaineb Nadeem; Neal Patel; Vladimir Makarov; Snjezana Dogan; Richard J Wong; Eric J Sherman; Alan L Ho; Timothy A Chan; James A Fagin; Luc G T Morris Journal: Mol Cancer Res Date: 2021-10-11 Impact factor: 6.333
Authors: Nancy Y Lee; Nadeem Riaz; Vanessa Wu; Thomas Brinkman; Chiaojung J Tsai; Wanquing Zhi; James Fetten; Alan Ho; Richard J Wong; Ronald Ghossein; Michael Tuttle; James Fagin; David G Pfister; Eric Sherman Journal: Thyroid Date: 2022-06-21 Impact factor: 6.506
Authors: Anastasios Maniakas; Ramona Dadu; Naifa L Busaidy; Jennifer R Wang; Renata Ferrarotto; Charles Lu; Michelle D Williams; G Brandon Gunn; Marie-Claude Hofmann; Gilbert Cote; Jared Sperling; Neil D Gross; Erich M Sturgis; Ryan P Goepfert; Stephen Y Lai; Maria E Cabanillas; Mark Zafereo Journal: JAMA Oncol Date: 2020-09-01 Impact factor: 31.777
Authors: Orla A Houlihan; Richard Moore; Muhammad F Jamaluddin; Adrinda Sharifah; Henry Paul Redmond; Seamus O'Reilly; Linda Feeley; Patrick Sheahan; Kathy Rock Journal: Rep Pract Oncol Radiother Date: 2021-06-09